Thus, combining mTORC1 inhibition with ferroptosis induction could be a promising therapeutic strategy for cancers with PI3K-AKT pathway mutations, demonstrating significant tumor regression in mouse xenograft models (Battaglia et al., 2020). Here, AKT1 is linked to cancer.